Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30426682 | 1.00 | CYP11B2 (0.47) | CYP11B2CYP11B1MAPTELANEG6PD | |
| SCHEMBL31276916 | 0.85 | DHODH (0.47) | ATMALDH1A1 | |
| SCHEMBL29364970 | 0.85 | CYP11B2 (0.47) | CYP11B2CYP11B1MAPTELANEG6PD | |
| SCHEMBL25206285 | 0.85 | CYP11B2 (0.47) | CYP11B2CYP11B1MAPTELANEG6PD | |
| SCHEMBL25358905 | 0.84 | CYP11B2 (0.49) | CYP11B2CYP11B1MAPTELANEG6PD | |
| SCHEMBL25206359 | 0.80 | MAPT (0.47) | CYP11B2CYP11B1MAPTELANEG6PD | |
| SCHEMBL29052562 | 0.79 | CYP11B2 (0.45) | CYP11B2CYP11B1MAPTELANEG6PD | |
| SCHEMBL15519378 | 0.76 | CHEK1 (0.41) | ELANEALDH1A1TSHR | |
| SCHEMBL29367068 | 0.74 | NAMPT (0.41) | CYP11B2CYP11B1MAPTELANEG6PD | |
| SCHEMBL26238112 | 0.74 | NAMPT (0.41) | CYP11B2CYP11B1MAPTELANEG6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286923-A1 | QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286923-A1 | QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4185380-A1 | QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF | Inipharm, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-116194440-A | Quinazolinone HSD17B13 inhibitors and uses thereof | 伊尼制药公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022020730-A1 | QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286923-A1 | QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B1, HSD17B13 | CYP11B2 20/4885CYP11B1 12/4885MAPT 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.